Zymosan
Residual Disease
George T. BuddEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Residual Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cc-5013 University of Chicago | Phase 2 | B |
DEXAMETHASONE University of Chicago | Phase 2 | B |
mln9708 University of Chicago | Phase 2 | B |
Datopotamab Deruxtecan UNC Lineberger Comprehensive Cancer Center | Phase 2 | CCC |
Wokvac Vaccine H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
Zymosan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →